NEW YORK (360Dx) – Protagen said today it has entered a collaboration with the University of California, San Francisco to use the company’s SeroTag platform for research into immunotherapies for prostate cancer.
The collaboration will use Protagen’s technology to predict patient response to immunotherapy treatment and to monitor patients for adverse effects, including development of so-called cold tumors that respond poorly to immunotherapy, the company said.
Financial and other terms of the deal were not disclosed.
